PATRICK G. MCALINNEY, M.D.
To the editor: We read with interest the letter by Cantarell and colleagues (1) which reported death, due to oligoanuric renal failure, in five patients treated with a formulation of 1% silver sulfadiazine.
It is unfortunate that the authors do not specify the formulation used to treat these patients, particularly since they report that a new formulation had just been introduced by their pharmacy. We note with concern that at least one adverse experience abstracting service (2) failed to identify the formulation, going as far as to quote directly that ". . . the continued application of the product.
MCALINNEY PG. Silver Sulfadiazine and Oliguric Renal Failure. Ann Intern Med. ;107:264. doi: 10.7326/0003-4819-107-2-264_2
Download citation file:
Published: Ann Intern Med. 1987;107(2):264.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use